Deciphering the anticancer mechanisms of sunitinib.
Pal
Sumanta Kumar
SK
Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA. spal@coh.org
Figlin
Robert A
RA
Yu
Hua
H
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D020869:Gene Expression Profiling; D007211:Indoles / Q000494:pharmacology*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D051379:Mice; D008954:Models, Biological; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000517:prevention & control*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011758:Pyrroles / Q000494:pharmacology*; D000077210:Sunitinib; D047368:Tumor Burden / Q000187:drug effects; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000235:genetics / Q000378:metabolism; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2; D000077210:Sunitinib